|
Fouad Al-Baaj 2005
|
LC 375-2250 mg/d
|
Placebo
|
36
|
4
|
HD
|
|
Melanie S. Joy 2003
|
LC 375 mg, 750 mg, 1500 mg, 2250 mg, 3000 mg/day
|
Placebo
|
93
|
4
|
HD and CAPD
|
|
Finn WF 2006
|
LC<3000 mg/d (serum phosphate ≤5.9 mg/dl)
|
pre-study phosphate binder (serum phosphate ≤5.9 mg/dl)
|
1359
|
104
|
HD
|
|
Patrick. C 2003
|
LC<3750 mg/d
|
CC<9000 mg/d
|
98
|
52
|
HD
|
|
N. D TOUSSAINT 2011
|
LC (serum phosphate in the normal range)
|
CC (serum phosphate in the normal range)
|
45
|
72
|
HD and CAPD
|
|
T.shigematsu 2008
|
LC+CC-liked placebo 750, 1500, 2250 mg/d (serum phosphate at 3.5-5.5 mg/dl)
|
CC+LC-liked placebo 1500, 3000, 4500 mg/d(serum phosphate 3.5-5.5 mg/dl)
|
258
|
8
|
HD
|
|
H H Mallache 2008
|
LC<3000mg/d (serum phosphate≤5.9mg/dl)
|
Previous phosphate binder (serum phosphate ≤5.9 mg/dl)
|
65
|
52
|
HD
|
|
T.shigematsu 2007
|
LC 750 mg, 1500 mg, 2250 mg, 3000 mg/day
|
Placebo
|
142
|
6
|
HD
|
|
Spasovski GB 2006
|
LC<3000 mg/d (serum phosphate <1.8 mmol/L)
|
CC< 4000 mg/d (serum phosphate <1.8 mmol/L)
|
24
|
52
|
Not describe
|
|
A.J. Hutchison 2005
|
LC 250-3000 mg/d
|
CC 1000-9000 mg/d
|
767
|
25
|
HD
|
|
S.-S. Chiang 2005
|
LC 375-3000 mg/d (can’t change during study)
|
Placebo
|
61
|
4
|
HD
|
|
Finn WF 2004
|
LC 225 mg, 675 mg, 1350 mg, 2250 mg/day
|
Placebo
|
144
|
6
|
HD
|
|
Yong Kyu Lee 2013
|
LC 1500 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl
|
CC 3000 mg at start, regulate to control the serum phosphate at 3.5-5.5 mg/dl
|
50
|
24
|
CAPD
|
|
Xu 2013
|
LC 1500 mg-3000 mg/day
|
Placebo
|
230
|
4
|
HD and CAPD
|
|
Sprague S.M 2009
|
LC 3,000 mg/day
|
SH 6,400 mg/day
|
333
|
4
|
HD
|
|
Kasai S 2012
|
LC 375–2250 mg/day
|
SH 750–9000 mg/day
|
84
|
13
|
HD
|
